Pfizer Licenses TB Drug Sutezolid To Medicines Patent Pool
Deal Could Speed Up Development After Six-Year Hiatus
Pfizer and the Medicines Patent Pool have signed a licensing agreement for the US firm’s investigational TB compound, sutezolid. The move should help to speed up the availability of the product, whose development appears to have been stalled since 2013.
